Figure 3.

Continuation rates and disease activity for each drug. (a) The proportion of patients with knee joint symptoms at the initiation of b/tsDMARDs treatment who continued therapy for 3 months. **; p < 0.01, by Chi-square test (b) Baseline disease activity (c) Disease activity after 3 months of treatment. (d) The difference in disease activity from baseline after 3 months of treatment. (e) Disease activity after 6 months of treatment. (f) The difference in disease activity from baseline after 6 months of treatment. *; p < 0.05, **; p < 0.01, ***; p < 0.001 by Steel–Dwass test. DAS28-ESR, disease activity score 28-joint count with erythrocyte sedimentation rate; CDAI, clinical disease activity index; SDAI, simplified disease activity index